New combo attack on liver cancer shows promise in early trial
NCT ID NCT07268131
First seen Jan 06, 2026 · Last updated May 10, 2026 · Updated 17 times
Summary
This study tests a two-step approach for people with liver cancer that is too advanced for standard transplant criteria but still removable by surgery. First, patients receive chemoembolization (TACE) plus an immunotherapy drug (QL1706) to shrink the tumor before surgery. After surgery, they continue QL1706 alone to help prevent the cancer from coming back. The main goal is to see if at least 90% of the tumor is killed by the pre-surgery treatment. About 30 adults with BCLC stage A or B liver cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.